News2020-08-14
Announces Positive Results of Preclinical Data for its vaccine candidate against COVID-19
無標題文件

Medigen Vaccine Biologics Corp. Announces Positive
Results of Preclinical Data for its vaccine
candidate against COVID-19

Aug 14, 2020

Medigen Vaccine Biologics Corp. (MVC) (TPEx 6547.TWO) today published preclinical
results of their COVID-19 vaccine candidate in BioRxiv, a non-peer reviewed, open
access preprint repository for the biological sciences:
Pre-print paper can be found here: bioRxiv
In the studies conducted, the S-2P antigen was combined with various adjuvants
to determine best immune response, administered to mice to test its ability in
eliciting SARS-CoV-2 neutralizing antibodies, and administered to rats to
investigate safety.

Key findings:

  • S-2P combined with adjuvants elicit effective neutralizing antibody in preclinical studies.

  • S-2P in combination with CpG 1018 and alum was found to be the most potent
    immunogen and induced a high titer of spike-specific antibodies in sera of immunized mice.

  • CpG 1018 is dominant over alum in directing the cell-mediated response towards a Th1
    response, while retaining high antibody levels. A potential important finding for the
    possible preventions of vaccine-associated enhanced respiratory disease (VAERD) in humans.

  • S-2P with CpG 1018 and alum was effective in inducing potent neutralization activity
    against both pseudovirus of Wuhan and European variants, as well as wild-type
    SARS-CoV-2, indicating the potential for broad spectrum protection.

  • No vaccine-related serious adverse effects were found in the dose-ranging study in
    rats administered in single- and two-dose regimens with up to 50 μg of S-2P combined
    with CpG 1018 alone or CpG 1018 with alum.

  • The two-dose regimen of S-2P formulated with CpG 1018 and alum induced potent
    neutralizing activity, and data justifies the evaluation of single-dose regimen in future studies.

  • There were high degrees of correlation between neutralization titers of pseudovirus,
    wild-type virus, and anti-S IgG titers.

The data has been submitted to the Taiwan regulatory authorities (TFDA) and MVC expects
to move forward with first-in-human clinical trials in the very near future.

Forward-Looking Statements
By their very nature, forward-looking statements for a development process involve inherent
risks and uncertainties, both general and specific. Thus there is no assurance or guarantee
that any predictions, forecasts, projections and other forward-looking statements will be achieved.


Given the unprecedented circumstances of the COVID-19 pandemic, regulatory uncertainty,
funding and rapid production development schedule, all numbers presented as well as schedule
must be subject to adaptations and change.


Medigen Contact:
Paul Torkehagen,
Director, Overseas Business Development

paul@medigenvac.com